ReviewVascular health and risk management2016
Biomarkers and the prediction of atrial fibrillation: state of the art.
Review in Vascular health and risk management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Correlation between vascular adhesion protein-1 and major adverse cardiovascular events in patients with atrial fibrillation.Frontiers in cardiovascular medicine · 2025Article
- Blood urea nitrogen to serum albumin ratio as a prognostic marker for 28-day mortality in atrial fibrillation: a retrospective cohort study.Frontiers in cardiovascular medicine · 2025Article
- Early Detection of Atrial Fibrillation in Chronic Obstructive Pulmonary Disease Patients.Medicina (Kaunas, Lithuania) · 2024Review
- Predictive value of soluble suppression of tumorigenicity 2 in atrial fibrillation: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2023Review
- A Differential Profile of Biomarkers between Patients with Atrial Fibrillation and Healthy Controls.Journal of personalized medicine · 2022Article
- The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates.Frontiers in cardiovascular medicine · 2022Review
- Association Between Apelin and Atrial Fibrillation in Patients With High Risk of Ischemic Stroke.Frontiers in cardiovascular medicine · 2021Article
- Prediction of Atrial Fibrillation Using Machine Learning: A Review.Frontiers in physiology · 2021Review
- Article
- Red blood cell distribution width: A marker of anisocytosis potentially associated with atrial fibrillation.World journal of cardiology · 2019Review
- Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiopoietin-2 and Atrial Fibrillation.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Article
- Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction.ESC heart failure · 2018Article
- Association between left atrial phasic conduit function and early atrial fibrillation recurrence in patients undergoing electrical cardioversion.Clinical research in cardiology : official journal of the German Cardiac Society · 2018Article
- Incidence of atrial fibrillation and its risk prediction model based on a prospective urban Han Chinese cohort.Journal of human hypertension · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice, and it places a substantial burden on the health care system. Despite improvements in our understanding of AF pathophysiology, we have yet to develop targeted preventive therapies. Recently, numerous biological markers have been identified to aid in the prediction of future AF events. Subclinical markers of atrial stress, inflammation, endothelial dysfunction, kidney dysfunction, and atherosclerosis have been linked to AF. The connection between these markers and AF is the identification of subclinical states in which AF propagation is likely to occur, as these conditions are associated with abnormal atrial remodeling and fibrosis. Additionally, several risk scores have been developed to aid in the identification of at-risk patients. The practicing clinician should be aware of these subclinical markers, as several of these markers improve the predictive abilities of current AF risk scores. Knowledge of these subclinical markers also provides clinicians with a better understanding of AF risk factors, and the opportunity to reduce the occurrence of AF by incorporating well-known cardiovascular disease risk factor modification strategies. In this review, we highlight several novel biological markers that have improved our understanding of AF pathophysiology and appraise the utility of these markers to improve our ability to predict future AF events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.